Insider Selling: Pharvaris (NASDAQ:PHVS) CFO Sells 10,000 Shares of Stock

by · The Cerbat Gem

Pharvaris N.V. (NASDAQ:PHVS – Get Free Report) CFO David Nassif sold 10,000 shares of the stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $30.31, for a total transaction of $303,100.00. Following the transaction, the chief financial officer owned 120,300 shares in the company, valued at approximately $3,646,293. This trade represents a 7.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Pharvaris Trading Up 0.7%

NASDAQ:PHVS traded up $0.20 during trading hours on Tuesday, reaching $29.88. The company had a trading volume of 191,721 shares, compared to its average volume of 227,155. The firm has a market cap of $1.95 billion, a price-to-earnings ratio of -9.40 and a beta of -2.34. The firm’s 50 day moving average price is $28.52 and its 200-day moving average price is $26.90. Pharvaris N.V. has a 52 week low of $15.46 and a 52 week high of $33.33.

Pharvaris (NASDAQ:PHVS – Get Free Report) last announced its earnings results on Tuesday, May 12th. The company reported ($0.70) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.12. On average, analysts forecast that Pharvaris N.V. will post -3.25 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently weighed in on PHVS shares. Wolfe Research assumed coverage on Pharvaris in a research report on Thursday, April 9th. They set an “outperform” rating and a $42.00 target price on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Pharvaris in a research note on Tuesday, April 21st. Wall Street Zen upgraded shares of Pharvaris from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 16th. Royal Bank Of Canada cut their price target on Pharvaris from $52.00 to $51.00 and set an “outperform” rating for the company in a research note on Monday, April 6th. Finally, Citigroup reissued a “buy” rating on shares of Pharvaris in a report on Wednesday, April 15th. Ten research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Pharvaris currently has a consensus rating of “Moderate Buy” and an average target price of $49.18.

View Our Latest Stock Report on Pharvaris

Institutional Investors Weigh In On Pharvaris

Institutional investors and hedge funds have recently modified their holdings of the stock. GF Fund Management CO. LTD. purchased a new position in shares of Pharvaris in the fourth quarter worth $35,000. JPMorgan Chase & Co. boosted its position in shares of Pharvaris by 30.6% during the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after acquiring an additional 783 shares during the last quarter. China Universal Asset Management Co. Ltd. purchased a new position in Pharvaris during the third quarter valued at $75,000. Barclays PLC bought a new stake in Pharvaris in the 4th quarter valued at $77,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in Pharvaris in the 4th quarter valued at $86,000.

Pharvaris Company Profile

(Get Free Report)

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.

Recommended Stories